Becton Dickinson & Co (BDX)

Large-cap stocks have not exactly fallen out of favor, but the conversation around them has shifted.

Becton, Dickinson and Company (NYSE:BDX) is one of the world’s largest pure-play medical technology companies in the world.

Dividend strategies remain popular for several reasons. A big part of the appeal is the steady income they can provide.

We came across a bullish thesis on Becton, Dickinson and Company on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on BDX.

On February 11, Citi analyst Joanne Wuensch lifted her price recommendation on Becton, Dickinson and Company (NYSE:BDX) to $198 from $185.70 and maintained a Buy rating.

Dividend stocks have lagged the broader market recently. However, there are hints that this stretch of underperformance may be losing momentum.

Operator: To all sites on hold, we would like to thank you for your patience. Please continue to stand by. To all sites on hold, we would like to thank you for your patience.

I don't usually start the game plan on Wednesday, but that's when we get the employment report this time, and it's kind of screwed up because of the government shutdown.

On January 28, Piper Sandler analyst Jason Bednar lifted Becton, Dickinson and Company (NYSE:BDX)’s price recommendation to $205 from $190. The analyst maintained a Neutral rating.